SSG
KURA icon

Summit Securities Group’s Kura Oncology KURA Stock Holding History

Summit Securities Group’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-172
Closed -$1.14K – 1261
2025
Q1 		$1.14K Buy
+172
New +$1.34K ﹤0.01% 695
2024
Q4 		– Sell
-139
Closed -$3K – 782
2024
Q3 		$3K Buy
+139
New +$2.82K ﹤0.01% 458

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Securities Group's KURA Position: Q2 2025 in Review

Summit Securities Group sold out of Kura Oncology (KURA) in Q2 2025, closing a stake of 172 shares — an estimated $1.14K sold.

Summit Securities Group first reported a position in KURA in Q3 2024 and held it in 2 quarters. The position peaked at $3K in Q3 2024. 182 funds tracked by Wall St. Rank hold KURA as of Q2 2025.

  • Summit Securities Group reported no remaining Kura Oncology position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 172 Kura Oncology shares in Q2 2025, an estimated $1.14K.
  • Summit Securities Group first reported a position in Kura Oncology in Q3 2024 and held it in 2 quarters.
  • Summit Securities Group's Kura Oncology position peaked at $3K in Q3 2024.
  • 182 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.